These observations suggest that PDGFRB inhibitor has the potential to be considered as a therapeutic drug for C-AD, and PRKDC inhibitor as a potential drug target for C-CC, the inhibitor to block fatty acid metabolism for C-FAM. Here, PDGFRB is linked to Alzheimer disease.